Skip to main content
. 2025 Jan 3;10(1):104089. doi: 10.1016/j.esmoop.2024.104089

Figure 2.

Figure 2

Time to treatment failure according to drug class of 36 molecular targeted treatments in 30 patients. Index date is the starting date of treatment. Six patients were censored (+), four being on-treatment and two pausing treatment without progression. SMI includes four patients treated with PARPi. HER2, human epidermal growth factor receptor 2; ICI, immune check point inhibitor; PARPi, poly-ADP-ribose-polymerase inhibitor; SMI, small-molecule inhibitor.